|
|
News Breaks | | | | March 19, 2013 | | 07:32 EDT |  | PTN | Palatin Tech announces notification of patent allowance
Palatin Technologies announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/472,914. The application includes composition of matter claims on two of Palatin's most advanced melanocortin receptor-1 specific peptides. Palatin is conducting in vitro and animal in vivo studies with the peptides claimed in the allowed patent and with related peptides. Proposed indications under study include dermatologic indications such as vitiligo and erythropoietic protoporphyria, inflammatory bowel disease, ocular indications such as uveitis and dry eye, and nephritis and other kidney conditions. Palatin plans to designate an initial clinical lead peptide candidate in the first half of 2013 and start toxicology and other preclinical studies preparatory to filing an Investigational New Drug Application with the U.S. Food and Drug Administration. | |
|
News For PTN From The Last 14 Days Check below for free stories on PTN the last two weeks. |
|
|
| There are no results for PTN |
|
|
|
|
|
|
